Comparison of quality of life between 2-year and 3-or-more-year administration of leuprorelin acetate every-3-months depot in combination with tamoxifen as adjuvant endocrine treatment in premenopausal patients with endocrine-responsive breast cancer: a randomized controlled trial

Yasuo Ohashi, Eiichi Shiba, Hiroko Yamashita, Junichi Kurebayashi, Shinzaburo Noguchi, Hirotaka Iwase, Michihiro Yoshida, Tsukasa Fujimoto

Research output: Contribution to journalArticle

Abstract

Background: We conducted an open-label, randomized controlled trial evaluating the appropriate treatment duration of leuprorelin acetate 3-month depot, TAP-144-SR (3M), administered postsurgically every 3 months for 2 years versus 3 or more (up to 5) years, in combination with tamoxifen, for 5 years in premenopausal endocrine-responsive breast cancer patients and reported similar survival benefit in the two treatment groups. We hereby present patient-reported quality of life (QOL) data obtained from this trial. Methods: Three self-administered QOL questionnaires (QOL-ACD, QOL-ACD-B, FACT-ES subscale) were used, and the difference in QOL score changes between the two groups was analyzed using a mixed-effects model for repeated measures. Results: Eligible patients (N = 222) were randomly assigned to a 2-year (2YG, N = 112) or 3-or-more-year treatment group (3YG, N = 110). The time courses of the three QOL scores during the trial period were similar in the two groups. The mean changes in the QOL scores from week 96 were largely stable through week 240 in the 3YG, but showed significantly greater improvement in the score changes from week 96 in the 2YG than the 3YG. Symptoms associated with menopause such as hot flashes and sweating contributed to these results. Menstruation recovery was associated with significantly greater improvement of these symptoms in the 2YG than the 3YG. Conclusions: Patient-reported menopause-associated symptoms and QOL improved after discontinuation of the LH-RH agonist administration and menstruation recovery. QOL information should be a consideration in long-term treatment.

Original languageEnglish
Pages (from-to)933-945
Number of pages13
JournalSupportive Care in Cancer
Volume26
Issue number3
DOIs
Publication statusPublished - Mar 1 2018
Externally publishedYes

Fingerprint

Leuprolide
Tamoxifen
Acetates
Randomized Controlled Trials
Quality of Life
Breast Neoplasms
Therapeutics
Menstruation
Menopause
Hot Flashes
Sweating
Gonadotropin-Releasing Hormone

Keywords

  • Adjuvant endocrine therapy
  • Leuprorelin acetate
  • Luteinizing hormone-releasing hormone agonist
  • Premenopausal endocrine-responsive breast cancer
  • Quality of life

ASJC Scopus subject areas

  • Oncology

Cite this

Comparison of quality of life between 2-year and 3-or-more-year administration of leuprorelin acetate every-3-months depot in combination with tamoxifen as adjuvant endocrine treatment in premenopausal patients with endocrine-responsive breast cancer : a randomized controlled trial. / Ohashi, Yasuo; Shiba, Eiichi; Yamashita, Hiroko; Kurebayashi, Junichi; Noguchi, Shinzaburo; Iwase, Hirotaka; Yoshida, Michihiro; Fujimoto, Tsukasa.

In: Supportive Care in Cancer, Vol. 26, No. 3, 01.03.2018, p. 933-945.

Research output: Contribution to journalArticle

@article{ac09f25cab0947bf8e76c1dc21bc615d,
title = "Comparison of quality of life between 2-year and 3-or-more-year administration of leuprorelin acetate every-3-months depot in combination with tamoxifen as adjuvant endocrine treatment in premenopausal patients with endocrine-responsive breast cancer: a randomized controlled trial",
abstract = "Background: We conducted an open-label, randomized controlled trial evaluating the appropriate treatment duration of leuprorelin acetate 3-month depot, TAP-144-SR (3M), administered postsurgically every 3 months for 2 years versus 3 or more (up to 5) years, in combination with tamoxifen, for 5 years in premenopausal endocrine-responsive breast cancer patients and reported similar survival benefit in the two treatment groups. We hereby present patient-reported quality of life (QOL) data obtained from this trial. Methods: Three self-administered QOL questionnaires (QOL-ACD, QOL-ACD-B, FACT-ES subscale) were used, and the difference in QOL score changes between the two groups was analyzed using a mixed-effects model for repeated measures. Results: Eligible patients (N = 222) were randomly assigned to a 2-year (2YG, N = 112) or 3-or-more-year treatment group (3YG, N = 110). The time courses of the three QOL scores during the trial period were similar in the two groups. The mean changes in the QOL scores from week 96 were largely stable through week 240 in the 3YG, but showed significantly greater improvement in the score changes from week 96 in the 2YG than the 3YG. Symptoms associated with menopause such as hot flashes and sweating contributed to these results. Menstruation recovery was associated with significantly greater improvement of these symptoms in the 2YG than the 3YG. Conclusions: Patient-reported menopause-associated symptoms and QOL improved after discontinuation of the LH-RH agonist administration and menstruation recovery. QOL information should be a consideration in long-term treatment.",
keywords = "Adjuvant endocrine therapy, Leuprorelin acetate, Luteinizing hormone-releasing hormone agonist, Premenopausal endocrine-responsive breast cancer, Quality of life",
author = "Yasuo Ohashi and Eiichi Shiba and Hiroko Yamashita and Junichi Kurebayashi and Shinzaburo Noguchi and Hirotaka Iwase and Michihiro Yoshida and Tsukasa Fujimoto",
year = "2018",
month = "3",
day = "1",
doi = "10.1007/s00520-017-3914-2",
language = "English",
volume = "26",
pages = "933--945",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Comparison of quality of life between 2-year and 3-or-more-year administration of leuprorelin acetate every-3-months depot in combination with tamoxifen as adjuvant endocrine treatment in premenopausal patients with endocrine-responsive breast cancer

T2 - a randomized controlled trial

AU - Ohashi, Yasuo

AU - Shiba, Eiichi

AU - Yamashita, Hiroko

AU - Kurebayashi, Junichi

AU - Noguchi, Shinzaburo

AU - Iwase, Hirotaka

AU - Yoshida, Michihiro

AU - Fujimoto, Tsukasa

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Background: We conducted an open-label, randomized controlled trial evaluating the appropriate treatment duration of leuprorelin acetate 3-month depot, TAP-144-SR (3M), administered postsurgically every 3 months for 2 years versus 3 or more (up to 5) years, in combination with tamoxifen, for 5 years in premenopausal endocrine-responsive breast cancer patients and reported similar survival benefit in the two treatment groups. We hereby present patient-reported quality of life (QOL) data obtained from this trial. Methods: Three self-administered QOL questionnaires (QOL-ACD, QOL-ACD-B, FACT-ES subscale) were used, and the difference in QOL score changes between the two groups was analyzed using a mixed-effects model for repeated measures. Results: Eligible patients (N = 222) were randomly assigned to a 2-year (2YG, N = 112) or 3-or-more-year treatment group (3YG, N = 110). The time courses of the three QOL scores during the trial period were similar in the two groups. The mean changes in the QOL scores from week 96 were largely stable through week 240 in the 3YG, but showed significantly greater improvement in the score changes from week 96 in the 2YG than the 3YG. Symptoms associated with menopause such as hot flashes and sweating contributed to these results. Menstruation recovery was associated with significantly greater improvement of these symptoms in the 2YG than the 3YG. Conclusions: Patient-reported menopause-associated symptoms and QOL improved after discontinuation of the LH-RH agonist administration and menstruation recovery. QOL information should be a consideration in long-term treatment.

AB - Background: We conducted an open-label, randomized controlled trial evaluating the appropriate treatment duration of leuprorelin acetate 3-month depot, TAP-144-SR (3M), administered postsurgically every 3 months for 2 years versus 3 or more (up to 5) years, in combination with tamoxifen, for 5 years in premenopausal endocrine-responsive breast cancer patients and reported similar survival benefit in the two treatment groups. We hereby present patient-reported quality of life (QOL) data obtained from this trial. Methods: Three self-administered QOL questionnaires (QOL-ACD, QOL-ACD-B, FACT-ES subscale) were used, and the difference in QOL score changes between the two groups was analyzed using a mixed-effects model for repeated measures. Results: Eligible patients (N = 222) were randomly assigned to a 2-year (2YG, N = 112) or 3-or-more-year treatment group (3YG, N = 110). The time courses of the three QOL scores during the trial period were similar in the two groups. The mean changes in the QOL scores from week 96 were largely stable through week 240 in the 3YG, but showed significantly greater improvement in the score changes from week 96 in the 2YG than the 3YG. Symptoms associated with menopause such as hot flashes and sweating contributed to these results. Menstruation recovery was associated with significantly greater improvement of these symptoms in the 2YG than the 3YG. Conclusions: Patient-reported menopause-associated symptoms and QOL improved after discontinuation of the LH-RH agonist administration and menstruation recovery. QOL information should be a consideration in long-term treatment.

KW - Adjuvant endocrine therapy

KW - Leuprorelin acetate

KW - Luteinizing hormone-releasing hormone agonist

KW - Premenopausal endocrine-responsive breast cancer

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=85031944336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031944336&partnerID=8YFLogxK

U2 - 10.1007/s00520-017-3914-2

DO - 10.1007/s00520-017-3914-2

M3 - Article

C2 - 29063390

AN - SCOPUS:85031944336

VL - 26

SP - 933

EP - 945

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 3

ER -